ProCE Banner Activity

The Importance of Molecular and Cytogenetic Targets in AML

Clinical Thought
New targeted agents are improving outcomes in newly diagnosed and relapsed/refractory AML. How can we optimize our diagnostic and treatment approaches for patients based on karyotype, FLT3 status, and other biomarkers?

Released: September 12, 2018

Expiration: September 11, 2019

No longer available for credit.

Share

Faculty

Eunice S. Wang

Eunice S. Wang, MD

Chief, Leukemia/Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

This activity is supported by educational grants from

Actinium

Astellas Text

Boston Biomedical

Celgene

Daiichi Sankyo, Inc.

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Faculty Disclosure

Primary Author

Eunice S. Wang, MD

Chief, Leukemia/Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Eunice S. Wang, MD, has disclosed that she has received consulting fees from Amgen and Pfizer and has served as a speaker for Jazz and Novartis.